{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T00:00:40Z","timestamp":1770508840887,"version":"3.49.0"},"reference-count":58,"publisher":"Informa UK Limited","issue":"11","funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Journal of Medical Economics"],"published-print":{"date-parts":[[2016,11,1]]},"DOI":"10.1080\/13696998.2016.1194278","type":"journal-article","created":{"date-parts":[[2016,5,25]],"date-time":"2016-05-25T19:20:43Z","timestamp":1464204043000},"page":"1061-1074","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":38,"title":["Cost-effectiveness of adding carfilzomib to lenalidomide and dexamethasone in relapsed multiple myeloma from a US perspective"],"prefix":"10.1080","volume":"19","author":[{"given":"Andrzej J.","family":"Jakubowiak","sequence":"first","affiliation":[{"name":"Myeloma Program, University of Chicago, Chicago, IL, USA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Campioni","sequence":"additional","affiliation":[{"name":"Global Health Economics, Amgen (Europe) GmbH, Zug, Switzerland;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c1gnes","family":"Benedict","sequence":"additional","affiliation":[{"name":"Modeling and Simulation, Evidera, Budapest, Hungary;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivan","family":"Houisse","sequence":"additional","affiliation":[{"name":"Modeling and Simulation, Evidera, Budapest, Hungary;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eszter","family":"Tichy","sequence":"additional","affiliation":[{"name":"Modeling and Simulation, Evidera, Budapest, Hungary;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andromachi","family":"Giannopoulou","sequence":"additional","affiliation":[{"name":"Global Health Economics, Amgen (Europe) GmbH, Zug, Switzerland;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanjay K.","family":"Aggarwal","sequence":"additional","affiliation":[{"name":"Global Development, Amgen Inc., Thousand Oaks, CA, USA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beth L.","family":"Barber","sequence":"additional","affiliation":[{"name":"Global Development, Amgen Inc., Thousand Oaks, CA, USA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sumeet","family":"Panjabi","sequence":"additional","affiliation":[{"name":"Global Health Economics, Amgen Inc. San Francisco, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2016,6,16]]},"reference":[{"key":"CIT0001","unstructured":"Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013. Available from: http:\/\/globocan.iarc.fr. Accessed March 28, 2016"},{"key":"CIT0002","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1011442"},{"key":"CIT0003","unstructured":"SEER. Surveillance, Epidemiology, and End Results Program. Stat Fact Sheets: Myeloma. Bethesda, Maryland: National Cancer Institute; 2016. http:\/\/seer.cancer.gov\/statfacts\/html\/mulmy.html. Accessed March 28, 2016"},{"key":"CIT0004","author":"Durie BG","year":"2012","journal-title":"J Clin Oncol"},{"key":"CIT0005","doi-asserted-by":"crossref","unstructured":"Dimopoulos MA, Lonial S, White D, et al. Eloquent-2 update: a phase 3, randomized, open-label study of elotuzumab in combination with lenalidomide\/dexamethasone in patients with relapsed\/refractory multiple myeloma - 3-year safety and efficacy follow-up. ASH Meeting, Presented by Meletios Dimopolous. Orlando, FL; December 5th, 2015","DOI":"10.1182\/blood.V126.23.28.28"},{"key":"CIT0006","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv325"},{"key":"CIT0007","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2012.01831.x"},{"key":"CIT0008","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-013-1991-4"},{"key":"CIT0009","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2710.2009.01153.x"},{"key":"CIT0010","doi-asserted-by":"crossref","first-page":"A450","DOI":"10.1016\/j.jval.2015.09.1134","volume":"18","author":"Potluri R","year":"2015","journal-title":"Value Health"},{"key":"CIT0011","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2015.1105202"},{"key":"CIT0012","volume-title":"Clinical practice guidelines in oncology. Multiple myeloma. National Comprehensive Cancer Network (NCCN), v3"},{"key":"CIT0013","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1411321"},{"key":"CIT0014","volume":"33","author":"Dimopoulos MA","year":"2015","journal-title":"J Clin Oncol"},{"key":"CIT0015","volume-title":"National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN),v2","author":"Multiple Myeloma, NCCN Evidence Blocks","year":"2016"},{"key":"CIT0016","unstructured":"Emanuel EJ. The solution to drug prices. New York: New York Times; 2015. http:\/\/www.nytimes.com\/2015\/09\/09\/opinion\/the-solution-to-drug-prices.html. Accessed April 14, 2016"},{"key":"CIT0017","unstructured":"Pollack A. Drug prices soar, prompting calls for justification. New York: New York Times; 2015. http:\/\/www.nytimes.com\/2015\/07\/23\/business\/drug-companies-pushed-from-far-and-wide-to-explain-high-prices.html. Accessed April 14, 2016"},{"key":"CIT0018","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X12472398"},{"key":"CIT0019","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0258(19970330)16:6<611::AID-SIM437>3.0.CO;2-T"},{"key":"CIT0020","unstructured":"Yong K, Delforge M, Driessen C, et\u00a0al. Multiple Myeloma Management: outcomes in Real-World Practice. Multiple myeloma management: outcomes in real-world practice. Poster presented at European Hematology Association congress, 11-14 June 2015. Poster number P649. Vienna, Austria: European Hematology Association; 2015"},{"key":"CIT0021","unstructured":"Truven Health Analytics 2013. RED BOOK. Ann Arbor, MI: Truven Health Analytics; 2016. Ann Arbor, MI http:\/\/sites.truvenhealth.com\/redbook\/index.html. Accessed May 18, 2016"},{"key":"CIT0022","doi-asserted-by":"publisher","DOI":"10.3111\/13696998.2015.1115407"},{"key":"CIT0023","unstructured":"CMS. Clinical Diagnostic Laboratory Fee Schedule. National Limit Payment (CPT code 83883). Baltimore, MD: CMS; 2014"},{"key":"CIT0024","unstructured":"HCUPnet National Inpatient Sample (NIS), Agency for Healthcare Research and Quality (AHRQ). National statistics by principal diagnosis code. Rockville, MD: Agency for Healthcare Research and Quality; 2013. http:\/\/hcupnet.ahrq.gov\/. Accessed March 29, 2016"},{"key":"CIT0025","unstructured":"Amgen Inc. Data on File. Retrospective study of healthcare utilization and costs in patients with multiple myeloma using Truven MarketScan Data Through December 2014. Thousand Oaks, CA, USA: Amgen Inc; 2015"},{"key":"CIT0026","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2004.01.019"},{"key":"CIT0027","unstructured":"Novartis. Panobinostat for treating multiple myeloma in people who have received at least one prior therapy. ID663 Single technology appraisal (STA) manufacturer's submission. Basel, Switzerland: Novartis; 2015. http:\/\/www.nice.org.uk\/guidance\/indevelopment\/gid-tag477\/documents. Accessed March 28, 2016"},{"key":"CIT0028","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-12-35"},{"key":"CIT0029","unstructured":"National Institute for Health and Care Excellence (NICE) technology appraisal guidance [TA 380]. Panobinostat for treating multiple myeloma after at least 2 previous treatments. England, UK: NICE; 2016. https:\/\/www.nice.org.uk\/guidance\/ta380. Accessed March 15, 2016"},{"key":"CIT0030","unstructured":"National Institute for Health and Care Excellence (NICE) technology appraisal guidance [TA338]. Pomalidomide for relapsed and refractory multiple myeloma previously treated with lenalidomide and bortezomib. England, UK: NICE; 2015. https:\/\/www.nice.org.uk\/guidance\/ta338. Accessed April 14, 2016"},{"key":"CIT0031","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.21.0534"},{"key":"CIT0032","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1405158"},{"key":"CIT0033","doi-asserted-by":"publisher","DOI":"10.1007\/s10198-012-0395-6"},{"key":"CIT0034","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-05-351726"},{"key":"CIT0035","unstructured":"Agnes Benedict, Eszter Tichy, Ivan Houisse, Arman Altincatal. Amgen Data on File. Economic evaluation of carfilzomib in the treatment of Relapsed Multiple Myeloma (RMM): cost-effectiveness Model (CEM) Technical Report. Thousand Oaks, CA, USA: Amgen; 2016"},{"key":"CIT0036","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00464-7"},{"key":"CIT0037","unstructured":"Institute for Clinical and Economic Review 2016. Treatment options for relapsed or refractory multiple myeloma: effectiveness, value, and value-based price benchmarks. Evidence Report. Boston, MA: Institute for Clinical and Economic Review; 2016. http:\/\/icer-review.org\/wp-content\/uploads\/2016\/05\/MWCEPAC_MM_Evidence_Report_050516-002.pdf. Accessed April 8, 2016"},{"key":"CIT0038","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa070594"},{"key":"CIT0039","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa070596"},{"key":"CIT0040","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1505654"},{"key":"CIT0041","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1516282"},{"key":"CIT0042","doi-asserted-by":"publisher","DOI":"10.1097\/MLR.0b013e31815c31a7"},{"key":"CIT0043","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.2011.0251"},{"key":"CIT0044","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.11-2-90"},{"key":"CIT0045","doi-asserted-by":"publisher","DOI":"10.1162\/rest.90.3.573"},{"key":"CIT0046","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2013.827188"},{"key":"CIT0047","unstructured":"Velcade\u00ae (bortezomib) FDA label - Prescribing Information. Food and Drug Administration. Cambridge, MA: Millennium Pharmaceuticals, Inc.; 2014. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/021602s040lbl.pdf. Accessed April 14, 2016"},{"key":"CIT0048","unstructured":"Cyclophosphamide FDA label - Prescribing Information. Food and Drug Administration. Deerfield, IL: Baxter Healthcare Corporation; 2013. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/012141s090,012142s112lbl.pdf. Accessed April 14, 2016"},{"key":"CIT0049","unstructured":"Doxorubicin hydrochloride FDA label \u2013 Prescribing Information. Food and Drug Administration. New York, NY: Pfizer, Inc.; 2013. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/050629s022lbl.pdf. Accessed April 14, 2016"},{"key":"CIT0050","unstructured":"Alkeran\u00ae (melphalan) FDA label \u2013 Prescribing Information. Food and Drug Administration. Research Triangle Park, NC: GlaxoSmithKline; 2007. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/014691s030lbl.pdf. Accessed April 14, 2016"},{"key":"CIT0051","unstructured":"Anthony Fields, Maureen Trudeau, Chaim Bell, et al. pan-Canadian Oncology Drug Review. pCODR Expert Review Committee (pERC) Final Recommendation for Bendamustine (Treanda) for iNHL. pERC Meeting 2012. https:\/\/www.cadth.ca\/sites\/default\/files\/pcodr\/pcodr-treandanhl-fn-rec.pdf. Accessed April 14, 2016"},{"key":"CIT0052","unstructured":"Food and Drug Administration. VePesid\u00ae (etoposide) FDA label. Princeton, New Jersey: Bristol-Myers Squibb; 2004. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2002\/019557s028lbl.pdf. Accessed April 14, 2016"},{"key":"CIT0053","unstructured":"Food and Drug Administration. CISplatin FDA label. Paramus, NJ: WG Critical Care, LLC. 2015. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/018057s083lbl.pdf. Accessed April 14, 2016"},{"key":"CIT0054","unstructured":"Pomalyst\u00ae (pomalidomide) FDA label - Prescribing Information. Food and Drug Administration. 2013. Summit, NJ: Celgene Corporation; 2013. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/204026lbl.pdf. Accessed April 14, 2016"},{"key":"CIT0055","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.37.4918"},{"key":"CIT0056","unstructured":"Rayos (prednisone) FDA label - Prescribing Information. Food and Drug Administration. Deerfield, IL: Horizon Pharma USA, Inc.; 2012. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/202020s000lbl.pdf. Accessed April 14, 2016"},{"key":"CIT0057","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-8-50"},{"key":"CIT0058","doi-asserted-by":"publisher","DOI":"10.3111\/13696998.2012.760159"}],"container-title":["Journal of Medical Economics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13696998.2016.1194278","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,6]],"date-time":"2020-09-06T20:04:35Z","timestamp":1599422675000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13696998.2016.1194278"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6,16]]},"references-count":58,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2016,11,1]]}},"alternative-id":["10.1080\/13696998.2016.1194278"],"URL":"https:\/\/doi.org\/10.1080\/13696998.2016.1194278","relation":{},"ISSN":["1369-6998","1941-837X"],"issn-type":[{"value":"1369-6998","type":"print"},{"value":"1941-837X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6,16]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2016-04-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-05-18","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-05-20","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-06-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}